Articles tagged with Metastasis
PharmaMar presents positive results of PM1183 (lurbinectedin) in a cohort of 36 patients with advanced and relapsed small-cell lung cancer (SCLC), achieving an objective response rate of 36%. This finding is significant given the limited therapeutic options for SCLC, which has a high mortality rate.
Researchers at The Wistar Institute have discovered a novel metastasis suppressor pathway orchestrated by the mitochondrial protein SNPH. This pathway promotes tumor cell proliferation in local growth but inhibits invasion and metastasis. By studying SNPH, scientists may uncover new therapeutic approaches to target metastatic cells.
The phase III RANGE trial showed that ramucirumab plus docetaxel significantly prolonged investigator-assessed progression-free survival compared to placebo plus docetaxel. The treatment also nearly doubled the objective response rate in patients with platinum-refractory advanced or metastatic urothelial cancer.
The KEYNOTE-059 trial found an overall objective response rate of 12% with pembrolizumab alone in pretreated patients, and more promising activity in patients with newly diagnosed metastatic cancer. The study also showed that patients with PD-L1 expression were more likely to respond to the treatment.
A team of researchers developed a tiny microfluidic device to track the long-term evolution of invasive cancer cells. The device allowed them to cultivate cells for up to three weeks, providing valuable insights into the biology of aggressive cells and potential targets for therapy.
Recent phase 3 studies (ALEX and ALUR trials) demonstrate alectinib's efficacy in treating non-small cell lung cancer (NSCLC) with central nervous system (CNS) involvement. The medication significantly decreases CNS progression, improving median progression-free survival by up to 8 months compared to standard chemotherapy.
Researchers at Children's Hospital Los Angeles are studying the role of extracellular vesicles, or exosomes, in cancer metastasis. Exosomes, released by cancer cells, can modify the behavior of surrounding cells, making them hospitable to cancer growth.
Researchers present a comprehensive overview of novel approaches to combating metastatic colorectal cancer, highlighting the potential of immunotherapies and targeted biological agents. The article discusses recent progress and future prospects for these treatments, including combination therapies and overcoming drug resistance.
A new research study reveals that a nanolaser called spaser can detect and kill circulating tumor cells in the bloodstream, preventing cancer metastases. The spaser is biocompatible and selectively targets cancer cells with high folate receptor expression.
A study using liquid biopsies found distinct genomic profiles in 99.7% of patients with CUP, harboring potentially targetable alterations. These findings suggest that liquid biopsies can guide treatment response in this patient population.
Scientists have found that breast cancer cells spread to other parts of the body relatively late in disease development. This discovery supports the importance of early diagnosis and treatment, which can increase the chances of preventing cancer cell spread and improving survival rates.
Researchers at McMaster University have discovered two new genes, SPOCK1 and TWIST2, that regulate brain metastases in lung cancer patients. These genes are present in the primary lung cancer of all patients with brain metastases but not in those without them.
Researchers at Johns Hopkins Medicine discovered a biochemical process that gives prostate cancer cells the ability to change shape and invade other tissues. The study found that a gene called AIM1 is deleted in approximately 20-30% of prostate cancers confined to the gland and 40% of metastatic prostate cancers.
A Tel Aviv University study finds that pre- and post-surgery administration of beta blockers and anti-inflammatory medication significantly reduces metastatic cancer recurrence. The treatment improves long-term survival rates and is safe, inexpensive, and easily administered.
Houston Methodist researchers have identified a distinct group of circulating tumor cells associated with breast cancer brain metastasis. This finding could lead to the development of more sensitive screening tools and real-time monitoring of disease progression and response to therapy.
A new study sequenced DNA and RNA of 500 patients with metastatic cancer, revealing a host of molecular factors driving tumor growth and spread. The analysis identified potential treatment targets and shed light on the underlying mechanisms behind metastatic cancer.
Researchers identified a new HER2 mutation that activates tyrosine kinase, triggering tumor formation. A circulating tumor DNA analysis was developed to diagnose and monitor patients with this mutation, showing promise for treatment with neratinib.
Researchers found manmade peptides significantly reduce metastasis in a mouse model of aggressive breast cancer. These peptides directly disrupt the WASF3 gene, which helps cancer cells move and invade other tissues.
Researchers at Cold Spring Harbor Laboratory have discovered an epigenetic factor, FOXA1, that reprograms gene enhancers in cancer cells, allowing them to 'remember' an earlier developmental state and become metastatic. This mechanism is a major breakthrough in understanding the spread of pancreatic cancer.
Researchers at VCU Massey Cancer Center have found a potential cure for colon cancer by targeting the gene CtBP with a drug called HIPP, which reduces pre-cancerous polyps by half and increases mouse lifespan. This breakthrough may also extend to other cancers depending on the same mechanism.
Researchers at UCI have developed a stem cell-based method that selectively targets and kills cancerous tissue while preventing side effects. By identifying unique physical properties of cancer cells, the treatment enables targeted therapy, reducing harm to healthy tissue.
Tumor cells develop resistance to immunotherapy by downregulating MHC class I molecules and triggering immunosuppressive processes. Inhibiting the epigenetic control protein Ezh2 improves treatment efficacy, leading to increased tumor mass shrinkage and extended tumor-free survival.
Inlighta Biosciences is developing a novel, protein-based MRI contrast agent called ProCA32 to detect early stages of liver cancers and other metastatic tumors. The agent has shown improved imaging contrast compared to conventional agents, enabling earlier detection and characterization of cancerous lesions.
Researchers have discovered new genes associated with the development of pheochromocytomas and paragangliomas, which are rare neuroendocrine tumors with a strong hereditary component. The study identifies alterations in enzymes involved in cell respiration as a key factor in tumor growth.
Research funded by NFCR finds two distinct patterns of metastatic spread in human colorectal cancer, where distant metastases originate directly from primary tumors without involving the lymph system. The study provides genetic evidence towards resolving the enigma of lymph node metastases and distant metastases.
A team of researchers at Brigham and Women's Hospital developed a potential therapy using stem cells loaded with oncolytic viruses to target skin cancer metastases in the brain. The study found that this approach led to the elimination of metastatic skin cancer cells from the brain, resulting in prolonged survival.
The EPICUP® test, based on DNA analysis, can correctly diagnose CUP in 70% of cases, increasing the detection rate from traditional methods' 30%. This leads to the development of more specific treatments for these patients.
Researchers have found that lymph node metastases are not always the source of cancer's spread to other organs, and instead, distant metastases can originate directly from the primary tumor. In most cases (65%), both lymph node and distant metastases originated from the same cell type in the primary tumor, indicating independent origins.
Scientists in Japan develop a method to image cancer at the single-cell level, revealing cancerous colonies in detail. The technique allows researchers to track cancer cells as they multiply and metastasize, providing insight into metastatic pathways.
Researchers have developed a method to visualize cancer metastasis in whole organs at the single-cell level, enabling early detection of dormant or resistant cancer cells. This breakthrough uses transparent mice and advanced imaging techniques to create 3-D maps of cancer cells throughout the body and organs.
Researchers developed an engineered opsonin protein to capture CTCs in the bloodstream, reducing detection time and increasing efficiency. The technology shows promise for improving cancer diagnostics by targeting specific carbohydrate molecules on CTCs.
Researchers at CNIO have developed a technique to study melanoma progression in mice, revealing unknown mechanisms and identifying new markers of metastasis. The MIDKINE protein has been identified as a key factor in melanoma metastasis, representing a new therapeutic target.
A study published in Oncogene has shed new light on the molecular mechanisms of ovarian cancer spread. Researchers found that N-cadherin plays a key role in metastasis by enabling cancer cells to anchor to new sites in the body, and that disrupting this process may provide a therapeutic strategy.
Researchers at Georgia Institute of Technology have developed a new treatment that prevents cancer cells from migrating and spreading, known as metastasis. The treatment uses locally administered gold nanorods heated by a low-energy laser to target and destroy cancer cells' leg-like protrusions, effectively halting their migration.
Researchers found that dual-agent PET/MR with time of flight detects more bone metastases in breast and prostate cancer patients, improving detection accuracy and reducing radiation dose. The study used combined imaging agents <sup>18</sup> F-FDG and <sup>18</sup> F-NaF to enhance image quality.
Researchers found that metastatic breast cancer cells signal neighboring cells through the GLI transcription factor, allowing otherwise anchored cells to metastasize. The discovery highlights a promising link in the hedgehog signaling pathway, which can be targeted to reduce metastatic potential.
A team of NYU researchers has pinpointed a sugar modification in cells that spurs the spread of skin cancer, specifically melanoma. The study reveals that silencing FUT8 enzyme suppresses cancer onset and tumor dissemination in laboratory mice.
A phase III clinical trial found that alectinib, a next-generation ALK inhibitor, extended the median time to progression by about 15 months compared to crizotinib. Alectinib also caused fewer severe side effects and was more effective in preventing brain metastases.
Researchers have discovered a novel mechanism behind treatment resistance in brain metastatic breast cancers, and a potential treatment strategy that may overcome this resistance. Targeting the Human Epidermal Growth Factor Receptor 3 (HER3) protein has been shown to significantly slow tumor growth and improve survival.
Researchers at MD Anderson Cancer Center present two combination therapies that significantly shrink metastatic brain tumors in over half of patients with stage IV melanoma. The trials demonstrate the feasibility of conducting clinical trials for these patients and offer new hope for those with brain metastases.
Adding abiraterone acetate to standard hormonal therapy reduces the chance of death by 38% and doubles the median time until cancer worsens. Cancer growth is delayed by 18 months, but severe side effects like high blood pressure and liver enzyme abnormalities are more common with abiraterone.
A phase III clinical trial shows that a single radiation treatment is as effective as a full week of radiation in relieving spinal cord compression symptoms. This breakthrough finding could help patients with advanced cancer spend more time focusing on the things they enjoy, without compromising care.
A study by researchers at the University of Freiburg found that activation of FOXO can induce tumors in stem cells without initial DNA damage. The team discovered that signals inducing this cancer come from surrounding tissues, including epidermis.
The omentum, a layer of fat over intestines, liver, and stomach, has immune functions and secretes hormones related to obesity. It also plays a role in cancer development, serving as a breeding ground for aggressive tumors.
Researchers are conducting a Phase 1 clinical trial using Lutetium 177Lu-PSMA-617 to target PSMA in men with progressive prostate cancer. The therapy aims to deliver precise radiation therapy and shrink the cancer, even in cases without visible tumors.
Researchers have developed a chemical array technique that can identify and culture malignant stem-like cells within melanoma tumors. This allows for the creation of patient-specific models for individualized cancer treatment.
Researchers discovered a biochemical signaling process that causes densely packed cancer cells to break away and spread the disease. The combined use of two existing drugs disrupts this process, significantly slowing cancer's tendency to travel.
A recent study led by Massachusetts General Hospital researchers has identified a novel mechanism behind the resistance of HER2-positive breast cancer metastases to treatment. The study found that overexpression of the HER3 gene contributes to this resistance, and combining anti-HER2 and anti-HER3 therapies can slow tumor growth.
A CNIO researcher has been funded by the Melanoma Research Alliance to study brain metastasis in melanoma, focusing on blocking cancer cell spread by targeting the microenvironment. The goal is to develop a new concept of treating metastasis in personalized medicine.
New study reveals that immune cells trained to recognize cancer can exit one tumor and move to another to attack cancerous cells. The research sheds light on how immune therapies for cancer might work and suggests new approaches to developing anti-cancer immune therapies.
Research reveals how hypoxia leads to inhibition of miR-34a, a key tumor suppressor, promoting metastasis and EMT. The findings suggest that targeting this process with drugs could be a therapeutic approach for treating metastasizing colon tumors.
Primary colorectal tumors secrete VEGF-A, inducing CXCL1 and CXCR2-positive myeloid-derived suppressor cells to recruit at distant sites, establishing niches for future metastases. Liver-infiltrating MDSCs facilitate tumor cell survival in the new location.
A large study found that brachytherapy is a good option for many men with penile cancer, offering high survival rates and minimal impact on sexual and urinary function. The treatment allowed 85% of men to survive with their penis intact, with few cases requiring surgery due to side effects.
Researchers have developed a new microscopic technique to analyze single melanoma cells, which are often irregular and dark, making them difficult to investigate. The technique, using modified photoacoustic spectroscopy, can detect non-uniform cancer cells and track their spread.
Scientists at Scripps Research Institute discovered that invasive tumors can send out tumor cells earlier than thought, which may seed secondary tumors years later. The escaping cells enter the bloodstream by entering blood vessels deep within the dense tumor core, upending the long-held belief about metastatic cell origin.
A global understanding of breast cancer dissemination is crucial to improve treatment, and this study reveals that most metastases originate from a single precursor. Analyzing the genomic profile of metastases can help make therapeutic decisions, particularly for targeted treatments.
A recent study published in The Journal of Urology found that surgery to remove secondary tumor growths, called metastases, significantly improves survival rates for patients with late-stage kidney cancer. Patients who underwent surgery had a life expectancy of three to 12 years, compared to eight months and two years without surgery.
Researchers developed a laboratory technique to test the effectiveness of treatments for breast cancer metastases in bone, mimicking interactions between cancer cells and bone cells. The 'bone-in culture array' model found that danusertib inhibits bone metastasis while other drugs stimulate growth of slow-growing cancer cells.
A study published in JAMA Surgery found that certain breast cancer patients who achieve pathologic complete response (pCR) after chemotherapy have a low risk of developing local metastases, making them candidates for less invasive treatment options. These patients may be able to avoid follow-up surgery, including axillary surgery.
FAU researchers identified Zeb1 as a key factor that activates embryonic programme, leading to rapid dissemination and metastasis in pancreatic cancer. They also found that blocking Zeb1 reduces metastatic capacity in other tumour types.